ADC · 폐암 (NSCLC) | 바이오모아

ADCBiologicstaleCullinan Therapeutics Inc.Phase 1

Dato-DXd (Datopotamab deruxtecan-dlnk, Datopotamab deruxtecan-dlnk (Dato-DXd))

Advanced Solid Tumor; NSCLC · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 74%임상시험 30상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 2

Vistusertib (Vistusertib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 9.5%임상시험 30상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 3

DS-1062a (DS-1062a)

Non-small Cell Lung Cancer · Metastatic Lung Cancer

#MetastaticLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 74%임상시험 28상태 ACTIVE

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 56%임상시험 28상태 RECRUITING

ADCBiologicstaleEMD Serono Research & Developme…Phase 2

Tepotinib (Tepotinib)

Non-small Cell Lung Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 54.7%임상시험 28상태 ACTIVE

ADCBiologicstaleBristol-Myers SquibbPhase 3

Amrubicin (Amrubicin)

Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 80%임상시험 25상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 2

AZD2936 (AZD2936)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 24상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 56%임상시험 24상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

HER3-DXd (HER3-DXd)

Carcinoma, Non-Small-Cell Lung · HER3

#HER3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 56%임상시험 22상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 1

CTM-1 Lyo-DP (HER3-DXd, HER3-DXd (CTM-1 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 56%임상시험 22상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 1

CTM-3 Lyo-DP (HER3-DXd, HER3-DXd (CTM-3 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 56%임상시험 22상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 1

MEDI5752 (MEDI5752)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 22상태 RECRUITING

ADCBiologicstaleBioNTech SEPhase 3

Pumitamig (Pumitamig)

Non-small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 19상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 3

Volrustomig (Volrustomig)

Metastatic Non-small Cell Lung Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 19상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Prostate Cancer; Prostatic Neoplasms · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3

임상시험 18상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

MK-1084 (MK-1084)

Malignant Neoplasm · Lung Neoplasm Malignant

#LungNeoplasmMalignant#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 18상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (Saruparib, Saruparib (AZD5305))

Ovarian Cancer; Lung Adenocarcinoma · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 18상태 RECRUITING

ADCBiologicstaleShanghai Junshi Bioscience Co.,…Phase 2

JS207 (JS207)

Non-squamous Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 15상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 2

Danvatirsen (Danvatirsen)

Advanced Colorectal Carcinoma; Advanced Lung Non-Small Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 11.1%임상시험 14상태 RECRUITING

ADCBiologicstaleHoffmann-La RochePhase 3

Divarasib (Divarasib)

Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer · Solid Tumors

#SolidTumors#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3

임상시험 13상태 RECRUITING

3 / 6 페이지

← 이전 다음 →

갱신 기록 없음 · 14일 주기 · 방문 16 / 568